Abstract
In this chapter we summarize the commonly used animal models employed in the study of cardiovascular diseases and diabetes, two of the most prevalent oxidative stress-induced diseases. A number of animal models of atherosclerosis support the notion that reactive oxygen and nitrogen species have a causal role in atherosclerosis and other vascular diseases. Experimental atherosclerosis is induced by specific lipid-rich diets or in genetically modified strains that cause hyperlipidemia and cardiovascular diseases. Rabbits are the animals most used for the study of atherosclerosis due to their facility to generate atherosclerosis with defined fat-enriched diets. Indeed, a myocardial infarction-prone derived from Watanabe LDL receptor-deficient rabbit strain is also used. Since mice are highly resistant to atherosclerosis, only genetically modified mice, such as the knock-out mouse for apo E, LDL receptor or both, have been used. In addition, reactive species also contribute to the pathogenesis of β-cell destruction in type 1 diabetes and β-dysfunction on type 2 diabetes. Alloxan induces the formation of reactive oxygen species and provokes β-cell death in type 1 and 2 diabetes mellitus, while streptozotocin involves DNA alkylation and fragmentation. Zucker rats are the most important animal models of genetic obesity and metabolic syndrome. Finally, genetically engineered diabetic models include transgenic and knock-out mice.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Davies KJ (1995). Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 61:1–31.
Rees DA, Alcolado JC (2005). Animal models of diabetes mellitus. Diabet Med 22:359–370.
Heistad DD, Wakisaka Y, Miller J, Chu Y, Pena-Silva R (2009). Novel aspects of oxidative stress in cardiovascular diseases. Circ J 73:201–207.
Tedgui A, Mallat Z (2006). Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515–581.
Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ (2004). Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 42:121–131.
Shiomi M, Fan J (2008). Unstable coronary plaques and cardiac events in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits: questions and quandaries. Curr Opin Lipidol 19:631–636.
Madamanchi NR, Hakim ZS, Runge MS (2005). Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 3:254–267.
Granada JF, Kaluza GL, Wilensky RL et al. (2009). Porcine models of coronary atherosclerosis and vulnerable plaque for imaging and interventional research. EuroIntervention 5:140–148.
Fernandez ML, Volek JS (2006). Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation. Nutr Metab (Lond) 27:3:17.
Yanni AE (2004). The laboratory rabbit: an animal model of atherosclerosis research. Lab Anim 38:246–256.
Hayashi T, Fukuto JM, Ignaro LJ, Chadhuri G (1992). Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 89:11259–11263.
Pfister SL (2006). Aortic thromboxane receptor deficiency alters vascular reactivity in cholesterol-fed rabbits. Atherosclerosis 189:358–363.
Zulli A, Buxton BF, Black MJ, Hare DL (2005). CD34 Class III positive cells are present in atherosclerotic plaques of the rabbit model of atherosclerosis. Histochem Cell Biol 124:517–522.
Shakuto S, Oshima K, Tsuchiya E (2005). Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 182:209–217.
Zhang ZS, Jame AE, Huang Y et al. (2005). Quantification and characterization of aortic cholesterol in rabbits fed a high-cholesterol diet. Int J Food Sci Nutr 56:359–366.
Ozer NK, Negis Y, Aytan N et al. (2006). Vitamin E inhibits CD36 scavenger receptor expression in hypercholesterolemic rabbits. Atherosclerosis 184:15–20.
Juzwiak S, Wojcicki j, Mokrzycki K, et al. (2005). Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. Pharmacol Rep 57:604–609.
Quiles JL, Mesa MD, Ramirez-Tortosa CL et al. (2002). Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arterioscl Thromb Vasc Biol 22:1225–1231.
Aguilera CM, Ramirez-Tortosa MC, Mesa MD, Ramirez-Tortosa CL, Gil A (2002). Sunflower, virgin olive and fish oils differentially affect the progression of aortic lesions in rabbits with experimental atherosclerosis. Atherosclerosis 162:335–344.
Ramirez-Tortosa MC, Mesa MD, Aguilera MC et al. (1999). Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effect in rabbits with experimental atherosclerosis. Atherosclerosis 147:371–378.
Ramirez-Tortosa MC, Aguilera CM, Quiles JL, Gil A (1998). Influence of dietary lipids on lipoprotein composition and LDL Cu(2+)-induced oxidation in rabbits with experimental atherosclerosis. Biofactors 8:79–85.
Quiles JL, Aguilera C, Mesa MD et al. (1998). An ethanolic-aqueous extract of Curcuma longa decreases the susceptibility of liver microsomes and mitochondria to lipid peroxidation in atherosclerotic rabbits. Biofactors 8:51–57.
Mesa MD, Aguilera CM, Ramirez-Tortosa CL et al. (2003). Oral administration of a turmeric extract inhibits erythrocyte and liver microsome membrane oxidation in rabbits fed with an atherogenic diet. Nutrition 19:800–804.
Ramirez-Tortosa MC, Quiles JL, Gil A, Mataix J (1997). Rabbit liver mitochondria coenzyme Q10 and hydroperoxide levels: an experimental model of atherosclerosis. Mol Aspects Med 18:233–236.
Aguilera CM, Mesa MD, Ramirez-Tortosa MC, Quiles JL, Gil A (2003). Virgin oil and fish oils enhance the hepatic antioxidant defense system in atherosclerotic rabbits. Clin Nutr 22:379–384.
Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD et al. (2009). Curcumin ameliorates rabbits’ steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free Radic Biol Med 47:924–931.
Watanabe Y (1980). Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL rabbit). Atherosclerosis 36:261–268.
Shiomi M, Ito T, Yamada S, Kawashima S, Fan J (2003). Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler Thromb Vasc Biol 23:1239–1244.
Shiomi M, Ito T, Tsukada T et al. (1994). Cell composition of coronary and aortic atherosclerotic lesions in WHHL rabbits differ. Arterioscler Thromb 14:931–937.
Ito T, Yamada S, Shiomi M (2004). Progression of coronary atherosclerosis relates to the onset of myocardial infarction in an animal model of spontaneous myocardial infarction (WHHLMI rabbits). Exp Anim 53:339–346.
Aikawa M, Libby P (2004). The vulnerable atherosclerotic plaque, pathogenesis and therapeutic approach. Cardiovasc Pathol 13:125–138.
Paigen B, Kovats SE, Chapman MH, Lin CY (1987). Characterization of a genetic difference in the platelet aggregation response of two inbred mouse strains, C57BL/6 and C3H/He. Atherosclerosis 64:181–190.
Jawień J, Nastałek P, Korbut R (2004). Mouse models of experimental atherosclerosis. J Physiol Pharmacol 55:503–517.
Feig JE, Quick JS, Fisher EA (2009). The role of a murine transplantation model of atherosclerosis regression in drug discovery. Curr Opin Investig Drugs 10:232–238.
Singh V, Tiwari RL, Dikshit M, Barthwal MK (2009). Models to study atherosclerosis: a mechanistic insight. Curr Vasc Pharmacol 7:75–109.
Zhang SH, Reddick RL, Piedrahita JA, Maeda N (1992). Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468–471.
Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL (1994). Apo E-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 14:605–616.
Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R (1994). Apo E-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14:133–140.
Reddick RL, Zhang SH, Maeda N (1998). Aortic atherosclerotic plaque injury in apolipoprotein E deficient mice. Atherosclerosis 140:297–305.
Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS (1994). The two-receptor model of lipoprotein clearance: tests of the hypothesis in “knock-out” mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 91:4431–4435.
Sullivan PM, Mezdour H, Quarfordt SH, Maeda N (1998). Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apo E with human Apo E*2. J Clin Invest 102:130–135.
Van den Maagdenberg AM, Hofker MH, Krimpenfort PJ et al. (1993). Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 268:10540–10545.
Hofker MH, van Vlijmen BJ, Havekes LM (1998). Transgenic mouse models to study the role of APO E in hyperlipidemia and atherosclerosis. Atherosclerosis 137:1–11.
Wouters K, Shiri-Sverdlov R, van Gorp PJ, van Bilsen M, Hofker MH (2005). Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apo E and LDLr mice. Clin Chem Lab Med 43:470–479.
Sullivan PM, Mezdour H, Aratani Y et al. (1997). Targeted replacement of the mouse apolipoprotein E gene with the common human APO E3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272:17972–17980.
Nieswandt B, Aktas B, Moers A, Sachs UJ (2005). Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost 3:1725–1736.
Srivastava N (2002). ATP binding cassette transporter A1--key roles in cellular lipid transport and atherosclerosis. Mol Cell Biochem 237:155–164.
Wu X, Wang J, Fan J et al. (2006). Localized vessel expression of lipoprotein lipase in rabbits leads to rapid lipid deposition in the balloon-injured arterial wall. Atherosclerosis 187:65–73.
Bailey EL, McCulloch J, Sudlow C, Wardlaw JM (2009). Potential animal models of lacunar stroke: a systematic review. Stroke 40:451–458.
Dejongste MJ, Terhorst GJ, Foreman RD (2009). Basic research models for the study of underlying mechanisms of electrical neuromodulation and ischemic heart-brain interactions. Cleve Clin J Med76:41–46.
Lenzen S, Drinkgern J, Tiedge M (1996). Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radical Biol Med 20:463–466.
Cnop M, Welsh N, Jonas JC et al. (2005). Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54:97–107.
Lenzen S (2008a). Oxidative stress: the vulnerable β-cell. Biochem Soc Trans 36:343–347.
Chen J, Gusdon AM, Thayer TC, Mathews CE (2008). Role of increased ROS dissipation in prevention of T1D. Ann NY Acad Sci 1150:157–166.
Eizirik DL, Mandrup-Poulsen T. (2001). A choice of death: the signal-transduction of immune-mediated β-cell apoptosis. Diabetologia 44:2115–2133.
Diakogiannaki E, Dhayal S, Childs CE et al. (2007). Mechanisms involved in the cytotoxic and cytoprotective actions of saturated versus monounsaturated long chain fatty acids in pancreatic β-cells. J Endocrinol 194:283–291.
Robertson R, Zhou H, Zhang T, Harmon JS (2007). Chronic oxidative stress as a mechanism for glucose toxicity of the β-cell in type 2 diabetes. Cell Biochem. Biophys 48:139–146.
Shafrir E (1992) Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev 8:179–208.
Bailey CJ, Flatt PR (2003). Animal syndromes resembling type 2 diabetes. In: Pickup JC, Williams G eds. Textbook of Diabetes, 3rd edn, Vol. 1. Oxford: Blackwell Science 25:1–30.
Hansen BC (1989). Pathophysiology of obesity-associated type II diabetes (NIDDM): implications from longitudinal studies of non-human primates. Nutrition 5:48–50.
Tesch GH, Allen TJ (2007). Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 12:261–266.
Lenzen S (2008b). The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51:216–226.
Federiuk IF, Casey HM, Quinn MJ, Wood MD, Ward WK (2004). Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: route of administration, pitfalls, and insulin treatment. Comp Med 54:252–257.
Gurley SB, Clare SE, Snow KP et al. (2006). Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 290:214–222.
Chen D, Wang MW (2005). Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 7:307–317.
Portha B, Blondel O, Serradas P et al. (1989). The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabetes Metab 15:61–75.
Reaven GM, Ho H (1991). Low-dose streptozotocin-induced diabetes in the spontaneously hypertensive rat. Metabolism 40:335–337.
Iwase M (1991). A new animal model of non-insulin-dependent diabetes mellitus with hypertension: neonatal streptozotocin treatment in spontaneously hypertensive rats. Fukuoka Igaku Zasshi 82:415–427.
Van Zwieten PA, Kam KL, Pijl AJ et al. (1996). Hypertensive diabetic rats in pharmacological studies. Pharmacol Res 33:95–105.
Luo J, Quan J, Tsai J et al. (1998). Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 47:663–668.
Reed MJ, Meszaros K, Entes LJ et al. (2000). A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49:1390–1394.
Etgen GJ, Oldham BA (2000). Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 49:684–688.
Aleixandre de Artiñano A, Castro MM (2009). Experimental rat models to study the metabolic syndrome. B J Nutr 1–9.
Pico C, Sánchez J, Oliver P, Palau A (2002). Leptin production by the stomach is up-regulated in obese (fa/fa) Zucker rats. Obesity Res 10, 932–938.
Beck B (2000). Neuropeptides and obesity. Nutrition 16:916–923.
Beck B, Richy S, Stricker-Krongrad A (2004). Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci 76:473–478.
Peterson RG, Neel MA, Little LA, Kincaid JC, Eichberg J (1990). Zucker diabetic fatty as a model for non-insulin-dependent diabetes mellitus. ILAR News 32:16–19.
Slieker LJ, Sundell KL, Heath WF et al. (1992). Glucose transporter levels in tissues of spontaneously diabetic Zucker fa/fa rat (ZDF/drt) and viable yellow mouse (Avy/a). Diabetes 41:187–193.
Kasiske BL, O’Donnell MP, Keane WF (1992). The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19:110–115.
Liao W, Angelin B, Rudling M (1997). Lipoprotein metabolism in the fat Zucker rat: reduced basal expression but normal regulation of hepatic low density lipoprotein receptors. Endocrinology 138:3276–3282.
Lash JM, Sherman WM, Hamlin RL (1989). Capillary basement membrane thickness and capillary density in sedentary and trained obese Zucker rats. Diabetes 38:854–860.
Kurtz TW, Morris RC, Pershadsingh HA (1989). The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13:896–901.
De Gasparo M (2002). AT(1) and AT(2) angiotensin II receptors key features. Drugs 1:1–10.
Picchi A, Gao X, Belmadani S et al. (2006). Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 99:69–77.
Griffen SC, Wang J, German MS (2001). A genetic defect in betacell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes 50:63–68.
Tokuyama Y, Sturis J, DePaoli AM et al. (1995). Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44:1447–1457.
Shimabukuro M, Ohneda M, Lee Y, Unger RH (1997). Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest 100:290–295.
Baudry A, Leroux L, Jackerott M, Joshi RL (2002). Genetic manipulation of insulin signaling, action and secretion in mice. EMBO Reports 4:323–328.
Kawano K, Hirashima T, Mori S, Natori T (1994). OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDMrat strain. Diabetes Res Clin Pract 24:317–320.
Bi S, Moran TH (2002). Actions of CCK in the controls of food intake and body weight: lessons from the CCK-A receptor deficient OLETF rat. Neuropeptides 36:171–181.
Man ZW, Zhu M, Noma Y et al. (1997). Impaired beta-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM. Diabetes 46:1718–1724.
Yanagita T, Nagao K (2008). Functional lipids and the prevention of the metabolic syndrome. Asia Pac J Clin Nutr 17:189–191.
Moran TH, Bi S (2006). Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors. Philos Trans R Soc Lond B Biol Sci 361:1211–1218.
Moran TH (2008). Unraveling the obesity of OLETF rats. Physiol Behav 22;94:71–78.
Baynes JW (1991). Role of oxidative stress in development of complications in diabetes, Diabetes 40:405–412.
Nam SM, Lee MY, Koh JH et al. (2009). Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property. Diabetes Res Clin Pract 83:176–182.
Portha B, Lacraz G, Kergoat M et al. (2009). The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes? Mol Cell Endocrinol 297:73–85.
Kowluru A (2008). Emerging roles for protein histidine phosphorylation in cellular signal transduction: lessons from the islet beta-cell. J Cell Mol Med 12:1885–1908.
Lacraz G, Giroix MH, Kassis N et al. (2009). Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. PLoS One 9;4:e6963.
Janssen U, Vassiliadou A, Riley SG, Phillips AO, Floege J (2004). The quest for a model of type II diabetes with nephropathy: the Goto Kakizaki rat. J Nephrol 7:769–773.
Yatoh S, Mizutani M, Yokoo T et al. (2006). Antioxidants and an inhibitor of advanced glycation ameliorate death of retinal microvascular cells in diabetic retinopathy. Diabetes Metab Res Rev 22:38–45.
Coleman DL (1980). Lessons from studies with genetic forms of diabetes in the mouse. Metabolism 32:162–164.
Kodama H, Fujita M, Yamazaki M, Yamaguchi I (1994). The possible role of age-related increase in the plasma glucagon/insulin ratio in the enhanced hepatic gluconeogenesis and hyperglycemia in genetically diabetic (C57BL/KsJ-db/db) mice. Jpn J Pharmacol 66:281–287.
Mariappan N, Elks CM, Sriramula S et al. (2010). NF-{kappa}B-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res. 85:473–483.
Allen TJ, Cooper ME, Lan HY (2004). Use of genetic mouse models in the study of diabetic nephropathy. Curr Diab Rep 4:435–440.
Feliers D, Duraisamy S, Faulkner JL et al. (2001). Activation of renal signaling pathways in db/db mice with type 2 diabetes. Kidney Int 60:495–504.
Coleman DL (1982). Obese and diabetes: two mutant genes causing diabetes–obesity syndromes in mice. Diabetes 31:1–6.
Haluzik M, Colombo C, Gavrilova O et al. (2004). Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology 145:3258–3264.
Sainsbury A, Schwarzer C, Couzens M, Herzog H (2002). Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 51:3420–3427.
Bartels ED, Lauritsen M, Nielsen LB (2002). Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 51:1233–1239.
O’Harte FP, Mooney MH, Kelly CM, McKillop AM, Flatt PR (2001). Degradation and glycemic effects of His (7)-glucitol glucagon-like peptide-1(7–36) amide in obese diabetic ob/ob mice. Regul Pept 96:95–104.
Gault VA, O’Harte FP, Harriott P et al. (2003). Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 46:222–230.
Rahimian R, Masih-Khan E, Lo M et al. (2001). Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem 224: 29–37.
Gum RJ, Gaede LL, Koterski SL et al. (2003). Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 52:21–28.
Sonta T, Inoguchi T, Tsubouchi H et al. (2004). Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic Biol Med 37:115–123.
Boudina S, Sena S, O’Neill BT et al. (2005). Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112:2686–2695.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Mesa, M.D., Aguilera, C.M., Gil, A. (2011). Experimental Models of Oxidative Stress Related to Cardiovascular Diseases and Diabetes. In: Basu, S., Wiklund, L. (eds) Studies on Experimental Models. Oxidative Stress in Applied Basic Research and Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-956-7_2
Download citation
DOI: https://doi.org/10.1007/978-1-60761-956-7_2
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-955-0
Online ISBN: 978-1-60761-956-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)